Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 2057-2066

  Mahasreshti, Parameshwar J ^a   Navarro, Jesus G ^a   Kataram, Manjula ^a   Wang, Ming H ^a   Nettelbeck, Dirk M ^a   Hemminki, Akseli ^a   Curiel, David T ^a   Siegal, Gene P ^b   Barnes, Mack N ^b   Alvarez, Ronald D ^b   Carey, Delicia ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ADENOVIRIDAE; ANIMALS; CELL DIVISION; CELL LINE; CLONING, MOLECULAR; DNA, COMPLEMENTARY; FEMALE; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS; SOLUBILITY; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 0034772251     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Cancer statistics 1996
2. Cancer statistics 1998
3. Gene therapy for ovarian carcinoma
4. Tumor angiogenesis-new drugs on the block
5. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
6. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor
7. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
8. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
9. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo
10. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
11. Tumor angiogenesis: Therapeutic implications
12. What is the evidence that tumors are angiogenesis dependent?
13. Tumor angiogenesis: Past, present and the near future
14. Vascular permeability factor gene expression in normal and neoplastic human ovaries
15. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms
16. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice
17. Angiogenesis in primary and metastatic epithelial ovarian carcinoma
18. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions
19. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma
20. Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer
21. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas
22. Vascular endothelial growth factor expression in early stage ovarian carcinoma
23. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels
24. Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining
25. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate
26. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors
27. Secretion of vascular endothelial growth factor in ovarian cancer
28. Tumor angiogenesis as a prognostic factor in ovarian carcinoma: Quantification of endothelial immunoreactivity by image analysis
29. Tumor angiogenesis in advanced stage ovarian carcinoma
30. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family
31. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
32. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
33. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
34. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
35. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
36. Complete inhibition of angiogenesis and growth of microtumors by antivascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
37. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/vascular permeability factor antibody
38. Halting angiogenesis suppresses carcinoma cell invasion
39. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
40. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
41. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
42. Angiostatin induces and sustains dormancy of human primary tumors in mice
43. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity
44. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1
45. Gene therapy-promises, problems and prospects
46. The body as a manufacturer of endostatin (news)
47. Antiangiogenic gene therapy
48. Gene therapy strategies for tumor antiangiogenesis
49. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis
50. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
51. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
52. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
53. Retroviral and adenoviral mediated transduction of angiostatin c DNA inhibits angiogenesis and tumor growth
54. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases
55. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes
56. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ
57. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
58. A simplified system for generating recombinant adenoviruses
59. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackie virus and adenovirus receptor-independent cell entry mechanism
60. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
61. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR
62. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids
63. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma
64. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer
65. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches
66. Adenoviral-mediated suicide gene therapy for ovarian cancer
67. A cancer gene therapy approach utilizing an anti-erbB-2 single chain antibody encoding adenovirus (AD21): A Phase I trial
68. Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid